Clinical Trial Update: A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sequential anlotinib followed by EP regimen with concurrent radiotherapy for unresectable stage III non-small cell lung cancer; status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• EP regimen

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Unresectable Stage III Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN